BioNJ Releases Strategic Plan to Strengthen New Jersey's $121 Billion Life Sciences Sector

BioNJ released a comprehensive white paper on Feb. 24 outlining an eight-year strategic plan to bolster New Jersey’s position as a national leader in life sciences, according to the industry advocacy organization.

The report, titled “Life Sciences in New Jersey: Prescription for Sustained Leadership,” draws on analysis from McKinsey to examine the current state of New Jersey’s life sciences sector and propose recommendations for sustained growth.

New Jersey’s biopharmaceutical industry generates $121 billion in economic impact, representing 7.8% of the state’s GDP and 2.5 times the U.S. average, according to BioNJ President and CEO Debbie Hart. The state ranks as the nation’s second-largest biopharma hub.

“New Jersey has long been a critical economic engine for the United States, and the biopharmaceutical industry has been a driving force behind the State’s growth for generations,” Hart said in the report.

New Jersey-based global biopharma companies generated $375 billion in revenue in 2024 and advanced more drug candidates than any other state, according to the white paper. The state also supports the nation’s largest and fastest-growing biopharma manufacturing workforce.

Despite these achievements, Hart noted that New Jersey still has “meaningful room to grow compared with hubs like Boston and the Bay Area.”

The white paper presents five key recommendations to capitalize on the state’s strengths and address growth opportunities.

The first recommendation calls for elevating New Jersey’s profile as a leading life sciences hub through enhanced marketing and outreach efforts.

BioNJ also recommends supporting a thriving startup and entrepreneurial ecosystem to foster innovation and attract new companies to the state.

The third recommendation focuses on talent development, specifically supporting the expansion of workforce training initiatives such as the NJ BioFutures program and the New Jersey Innovation and Research Fellowship Program, according to the report.

Manufacturing represents another key opportunity. The white paper recommends promoting New Jersey as the preferred U.S.-based manufacturing partner by continuing the Next New Jersey Manufacturing Program to spur investment and create manufacturing jobs. The report also suggests continuing the NJEDA manufacturing voucher program and expanding its scope to include equipment for research and development.

The final recommendation involves developing strategies to attract and expand into adjacent sectors. This includes promoting available lab space to strengthen New Jersey’s position as a center for research and clinical innovation while attracting contract research organizations and emerging biopharma firms. The report suggests potentially offering turnkey funding in exchange for commitments to job creation.

“BioNJ’s white paper serves as a guide to support the new administration’s efforts to attract investment, strengthen the start-up ecosystem and reinforce New Jersey’s position as a leading life sciences hub,” Hart said.

Chris Cozic, BioNJ’s chair and executive vice president and chief people officer for Genmab, emphasized the importance of building on recent progress.

“New Jersey’s life sciences industry has made significant progress in recent years, creating a powerful foundation for future growth,” Cozic said. “We now have an opportunity to build on this momentum and elevate New Jersey into a biopharma hub that sets the standard nationwide.”

The strategic plan comes as New Jersey seeks to maintain its competitive edge in the rapidly evolving life sciences sector. Hart noted that New Jersey has “the foundation and momentum to secure its leadership in the next era of life sciences.”

The white paper’s recommendations aim to help the state capitalize on existing strengths while addressing areas where competitors like Boston and the Bay Area currently hold advantages, according to BioNJ.